Patients treated with upadacitinib have lower rates of lung function decline with no significant adverse events.
Patients treated with upadacitinib had reduced rates of decline in forced vital capacity at 24 weeks of treatment compared to those treated withmofetil. After 1 year, the difference in the annual rate of decline between the two groups was 20.
9 mL/y, favoring upadacitinib< 80% of the predicted normal value, and at least 10% fibrosis scarring in a high-resolution CT scan. Patients were aged on average about 33 years, and 80% were women. Patients were randomly assigned in a 1:1 ratio to receive a daily dose of 15 mg upadacitinib or 2000 mg mycophenolate. Researchers assessed FVC decline at 12, 24, and 52 weeks, as well as DLCO and changes in the modified Rodnan skin score . At 52 weeks, 20.6% of the upadacitinib group and 37.5% of the mycophenolate group had ≥ 5% absolute decline from baseline in FVC. A 10% drop in FVC from baseline at 1 year was also more common in patients taking mycophenolate than in those taking upadacitinib . The change in DLCO at 52 weeks was -62.7 mL in the upadacitinib group and -93.3 mL in the mycophenolate group. The change from baseline in mRSS in patients with the diffuse type of SSc was numerically different between the two groups after 1 year, but this difference was not statistically significant. No significant adverse events were detected in either group. Because the age of the participants in this study trended younger, there may be a higher risk for these events as patients age, Szabo noted. “The problem we might have will be with older patients because we know all the adverse effects that JAK inhibitors have, and probably we should be a bit more cautious,” she said.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Rheumatoid Arthritis Of The Spine Spondyloarthritis Spondylosis Lung Systemic Sclerosis Diffuse Scleroderma Interstitial Lung Disease Rheumatoid Arthritis Rheumatoid Arthritis (RA) Juvenile Rheumatoid Arthritis Juvenile RA Juvenile Idiopathic Arthritis Juvenile Rheumatoid Arthritis (JRA) Juvenile Idiopathic Arthritis (JIA) JIA JRA
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Ethereum (ETH) Eyes $3,000, But One Thing RemainsEthereum outperforms top 10 cryptocurrencies in daily gains
Read more »
Ambience announces OpenAI-powered medical coding model that outperforms physiciansAmbience is part of the red-hot market that uses AI to draft clinical notes in real time as doctors consensually record their visits with patients
Read more »
Pound Sterling outperforms US Dollar as Trump tariffs strike US economic activityThe Pound Sterling (GBP) rises to near 1.3580 against the US Dollar (USD) during European trading hours on Thursday. The GBP/USD pair gains as the US Dollar struggles to gain ground after a sharp sell-off on Wednesday.
Read more »
SHIB Price Prediction: Shiba Inu Recovers Amid Massive $36M Whale Transaction; Still Stuck in Downward ChannelSHIB outperforms BTC amid reports of a massive whale transaction.
Read more »
Pound Sterling outperforms US Dollar, US-China trade talks under spotlightThe Pound Sterling (GBP) rises to near 1.3580 against the US Dollar (USD) during the European trading session on Monday. The GBP/USD pair gains as the US Dollar underperforms across the board amid uncertainty ahead of trade talks between the United States (US) and China in London later in the day.
Read more »
Altcoin Season: Ethereum outperforms Bitcoin as declining BTC dominance sirens Altseason aheadThe ongoing market recovery witnesses a surge in altcoins' market capitalization of over 5% so far this week, increasing the chances of an altseason as Ethereum (ETH) rally outperforms Bitcoin (BTC) in the last 90 days.
Read more »